Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter

BIOLOGICAL7 trials

Sponsors

Mayo Clinic

Conditions

Estrogen Receptor NegativeEstrogen Receptor PositiveFallopian Tube CarcinosarcomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous AdenocarcinomaFallopian Tube Serous AdenocarcinomaFallopian Tube Transitional Cell Carcinoma

Phase 1

Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer

CompletedNCT00408590

Mayo ClinicOvarian Cancer, Primary Peritoneal Cavity Cancer

Start: 2004-04-19End: 2017-11-07Updated: 2024-01-16

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma

CompletedNCT00450814

Mayo ClinicRecurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma

Start: 2006-11-30End: 2019-11-20Updated: 2019-12-16

Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma

CompletedNCT01503177

Mayo ClinicRecurrent Malignant Mesothelioma, Stage IA Malignant Mesothelioma, Stage IB Malignant Mesothelioma +3

Start: 2011-11-30End: 2019-04-11Updated: 2021-01-11

Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer

CompletedNCT01846091

Mayo ClinicEstrogen Receptor Negative, Estrogen Receptor Positive, Head and Neck Squamous Cell Carcinoma +8

Start: 2013-04-09End: 2019-11-26Updated: 2023-02-14

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Active, not recruitingNCT02068794

Mayo ClinicFallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma +15

Start: 2014-04-25End: 2026-09-01Updated: 2026-07-08

Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery

CompletedNCT02700230

Mayo ClinicMetastatic Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1, Recurrent Malignant Peripheral Nerve Sheath Tumor

Start: 2017-03-22End: 2024-04-17Updated: 2024-09-27

Phase 2

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

TerminatedNCT02364713

Mayo ClinicFallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma +24

Start: 2015-03-13End: 2022-01-13Updated: 2025-12-11

Related Papers

Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial

Clinical Cancer Research2023-10-0912 citations

Abstract P6-21-03: Phase I trial of intratumoral (IT) administration of a NIS-expressing derivative manufactured from a genetically engineered strain of measles virus (MV)

Cancer Research2019-02-156 citations

T cell responses to tumor associated antigens in multiple myeloma patients treated with MV-NIS, an oncolytic measles virus.

Journal of Clinical Oncology2018-02-101 citations

Overcoming oncolysis resistance by double infections with vaccine-derived state-of-the-art virotherapeutics

Zeitschrift für Gastroenterologie2013-08-16